Allergan PLC. (AGN) & NephroGenex (NRXGQ) Head-To-Head Comparison
NephroGenex (OTCMKTS: NRXGQ) and Allergan PLC. (NYSE:AGN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.
Valuation and Earnings
This table compares NephroGenex and Allergan PLC.’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Allergan PLC.||$14.57 billion||3.99||$14.97 billion||($22.50)||-7.77|
This table compares NephroGenex and Allergan PLC.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
81.2% of Allergan PLC. shares are owned by institutional investors. 0.4% of Allergan PLC. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Allergan PLC. pays an annual dividend of $2.80 per share and has a dividend yield of 1.6%. NephroGenex does not pay a dividend. Allergan PLC. pays out -12.4% of its earnings in the form of a dividend.
This is a summary of recent recommendations for NephroGenex and Allergan PLC., as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NephroGenex presently has a consensus price target of $17.50, indicating a potential upside of 624,900.00%. Allergan PLC. has a consensus price target of $245.00, indicating a potential upside of 40.10%. Given NephroGenex’s stronger consensus rating and higher probable upside, equities analysts clearly believe NephroGenex is more favorable than Allergan PLC..
Risk and Volatility
NephroGenex has a beta of -0.98, meaning that its stock price is 198% less volatile than the S&P 500. Comparatively, Allergan PLC. has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
Allergan PLC. beats NephroGenex on 9 of the 13 factors compared between the two stocks.
NephroGenex Company Profile
NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.
Allergan PLC. Company Profile
Allergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.
Receive News & Stock Ratings for NephroGenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NephroGenex Inc and related stocks with our FREE daily email newsletter.